SYRINGE DESIGN AND FILLING TECHNIQUE AFFECT ACCURACY OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INTRAVITREAL INJECTIONS
- PMID: 36729828
- DOI: 10.1097/IAE.0000000000003693
SYRINGE DESIGN AND FILLING TECHNIQUE AFFECT ACCURACY OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INTRAVITREAL INJECTIONS
Abstract
Purpose: To evaluate the effect of syringe design and filling technique on the accuracy of anti-vascular endothelial growth factor delivery.
Methods: Volume output was measured with three syringe designs: a 1.0-mL slip-tip syringe, a 1.0-mL Luer-lock syringe, and a ranibizumab prefilled syringe-using two filling techniques ("upward" and "downward") and two fluids (water and bevacizumab). A total of 300 simulated injections were performed. Accuracy was determined by difference from the intended volume of 50 µ L and by mean absolute percentage error.
Results: Volume outputs were significantly different between syringe designs, with mean values of 61.99 ± 4.18 µ L with the 1-mL slip-tip syringe, 57.43 ± 4.95 µ L with the Luer-lock 1-mL syringe, and 51.06 ± 4.74 µ L with the ranibizumab syringe, making the latter the most accurate syringe. There were 37 cases (12.3%) of underdosing below 50 µ L, the majority of which occurred with the ranibizumab syringe. The "downward" technique reduced the occurrence of air bubbles.
Conclusion: Intravitreal injections using 1.0-mL syringes are less accurate than using the ranibizumab prefilled syringe, which has a low-volume and low dead-space plunger design. The variability in volume output may result in less predictable treatment response, especially in cases of underdosing, which were more common with the ranibizumab syringe.
Comment in
-
Reply.Retina. 2025 Jan 1;45(1):e4. doi: 10.1097/IAE.0000000000004292. Retina. 2025. PMID: 39699859 No abstract available.
References
-
- Pearce W, Hsu J, Yeh S. Advances in drug delivery to the posterior segment. Curr Opin Ophthalmol 2015;26:233–239.
-
- Campbell RJ, Bronskill SE, Bell CM, et al. Rapid expansion of intravitreal drug injection procedures, 2000 to 2008: a population-based analysis. Arch Ophthalmol 2010;128:359–362.
-
- Lai TYY, Liu S, Das S, Lam DSC. Intravitreal injection–technique and safety. Asia Pac J Ophthalmol (Phila) 2015;4:321–328.
-
- Brown GC, Brown MM, Rapuano SB, Boyer D. A cost-benefit analysis of VEGF-inhibitor therapy for neovascular age-related macular degeneration in the United States. Am J Ophthalmol 2021;223:405–429.
-
- Kiss S, Campbell J, Almony A, et al. Management and outcomes for neovascular age-related macular degeneration: analysis of United States electronic health records. Ophthalmology 2020;127:1179–1188.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources